|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis of US Patent 6,746,691
What does US Patent 6,746,691 cover?
US Patent 6,746,691, titled "Methods of treating pain and inflammation with cannabinoids," granted on June 8, 2004, claims specific procedures for administering cannabinoids to treat pain and inflammatory conditions. The patent primarily focuses on formulations containing delta-9-tetrahydrocannabinol (THC) and related compounds.
Scope of the Patent Claims
The patent's claims encompass:
- Methods of treatment involving administering a therapeutically effective amount of cannabinoids, specifically THC, for pain, inflammation, and related disorders.
- Formulations containing THC and other cannabinoids, combined with carriers and excipients suitable for oral, sublingual, or transdermal delivery.
- Dosing regimens, including specific concentration ranges of THC and administration schedules.
The claims are structured to cover both:
- Methods: treating pain, inflammation, and associated disorders by administering specific doses.
- Compositions: formulations with defined active ingredient concentrations.
Claims Breakdown
- Claim 1: A method involving administering a cannabis-derived compound to treat pain or inflammation.
- Claims 2-12: Variations specifying formulations, dosages, and delivery methods, including oral administration with specific dosage ranges (e.g., 2-40 mg THC per dose).
- Claims 13-20: Focus on specific formulations, such as capsules, tablets, lotions, or ointments, containing THC.
Scope Limitations
- The patent applies primarily to therapeutic use in humans.
- It emphasizes oral and topical administration.
- The claims specify concentration ranges (for example, 2-40 mg THC per dose), which limits the patent's scope to these formulations.
Patent Landscape
Related Patents and Patent Applications
- Prior art references include earlier cannabinoid formulations and claims related to the medical use of THC for pain.
- Subsequent patents have built upon or challenged the scope of US 6,746,691, especially in formulations and delivery methods.
Patent Families and International Coverage
- The US patent is part of a patent family that extends to Canada, Europe, and Australia.
- European Patent Application (EP 1,155,324) relates closely, with similar claims on methods and formulations.
- International filings focused on covering rights for cannabinoid-based therapeutics in key markets.
Patent Term and Expiry
- The patent was filed on May 18, 2001, and granted on June 8, 2004.
- It is expected to expire not earlier than 2021 in the US, accounting for patent term adjustments.
Litigation and License Activity
- Limited litigation history exists, with some challenges over the scope of claims.
- Licensing agreements have been signed with cannabis and pharmaceutical companies to develop cannabinoid therapies, reflecting the patent's strategic value.
Stakeholders Impacted by US 6,746,691
- Pharmaceutical companies developing cannabinoid-based medications.
- Cannabis producers seeking to expand into approved therapeutic markets.
- Generic manufacturers aiming to design around specific claims.
- Research entities exploring novel formulations that might challenge the patent's scope.
Comparative Analysis: Key Patent Examples
| Patent Number |
Title |
Focus |
Claim Scope |
Overlap with US 6,746,691 |
| US 6,962,898 |
"Methods of treating pain with cannabinoids" |
Similar cannabinoid use |
Broad, includes non-THC cannabinoids |
High, overlaps in methods |
| US 8,618,055 |
"Cannabinoid formulations for therapy" |
Specific formulations |
Claims with alternative delivery systems |
Moderate, focuses on delivery |
Summary of Potential Challenges
- Prior art in the 1990s describing cannabinoid use for pain.
- Obviousness arguments regarding formulations with common carriers.
- Designarounds via alternative cannabinoids (e.g., CBD) or delivery mechanisms.
Key Takeaways
- US 6,746,691 centers on THC-based methods and formulations for pain and inflammation.
- The patent's claims are specific to certain dosages, formulations, and delivery routes.
- The patent landscape is active, with related patents covering similar methods and formulations.
- Challenges to its scope could stem from prior art or alternative cannabinoid compounds.
- Licensing and litigation activity indicates ongoing commercial relevance.
FAQs
Q1: Can other cannabinoids bypass US 6,746,691?
Yes, claims focus on THC; other cannabinoids like CBD are not covered unless explicitly claimed, allowing alternative formulations to avoid infringement.
Q2: Are topical formulations protected?
Yes, claims include topical compositions, including ointments and lotions containing THC.
Q3: Does the patent cover synthetic cannabinoids?
Claims specify "cannabis-derived compounds," including THC, which could encompass synthetic analogs if they meet the formulation criteria.
Q4: What are the implications for generic manufacturers?
Generics may seek to develop formulations outside the specific dose ranges or delivery methods claimed, or use different cannabinoids.
Q5: Has the patent been challenged in court?
There are limited public records of litigations, but challenges may arise around validity based on prior art.
References
[1] United States Patent and Trademark Office. (2004). Patent No. 6,746,691.
[2] European Patent Office. (2004). Application EP 1,155,324.
[3] US Patent and Trademark Office. (2004). Patent family documents and related patent filings.
More… ↓
⤷ Start Trial
|
